Nicotine salt with meta-salicylic acid and applications therein

Abstract

The present disclosure relates generally to the field of nicotine delivery. The disclosure teaches a nicotine meta-salicylate. More specifically, the disclosure teaches a condensation nicotine aerosol where nicotine meta-salicylate is vaporized. This disclosure relates to aerosol nicotine delivery devices. The delivery devices can be activated by actuation mechanisms to vaporize thin films comprising a nicotine meta-salicylate. More particularly, this disclosure relates to thin films of nicotine salt with meta salicylic acid for the treatment of nicotine craving and for effecting smoking cessation.

What is claimed is: 
     
         1 . A drug delivery and drug cessation system, comprising:
 a portable drug delivery device comprising a drug payload, a dosage delivery device, and a first wireless transceiver;   a portable control device comprising a second wireless transceiver, the portable control device being in wireless communication with the portable drug delivery device via the first wireless transceiver and the second wireless transceiver;   the portable drug delivery device being configured to deliver a drug to a body of a user based on instructions received from the portable control device;   wherein the portable drug delivery device is a vapor-based drug delivery device;   wherein the portable drug delivery device further comprises a breath actuator and a lockout unit, wherein the breath actuator is configured to cause the dosage delivery device to deliver a supplemental dose of the drug from the drug payload, based on a determination that the user has inhaled from the portable drug delivery device, and wherein the lockout unit is configured to prevent the breath actuator from causing the dosage delivery device to deliver the supplemental dose of the drug during a predetermined period based on a determination that the supplemental dose would exceed a predetermined maximum dose of the drug for the predetermined period; wherein the breath actuator is configured to cause the dosage delivery device to deliver the supplemental dose of the drug from the drug payload, based on a determination that the user has inhaled from the portable drug delivery device, without receiving the instructions from the portable control device and contrary to any preset dosage schedules.   
     
     
         2 . The drug delivery and drug cessation system of  claim 1 , wherein the drug payload comprises one or more foils coated with the drug, wherein the dosage delivery device comprises a heater configured to heat one of a portion of each foil or an entire surface of each foil to at least 200 degrees Celsius within less than 2 seconds. 
     
     
         3 . The drug delivery and drug cessation system of  claim 1 , wherein the heater is configured to heat one of a portion of each foil or an entire surface of each foil to at least 300 degrees Celsius within less than 0.5 seconds. 
     
     
         4 . The drug delivery and drug cessation system of  claim 1 , wherein the drug payload comprises a plurality of resistive coils connected in series and a plurality of fuses connected to a ground wire, each fuse separating each coil from a next adjacent coil in the series, wherein each of the plurality of coils is coated with the drug, wherein the dosage delivery device comprises a current source configured to heat each coil to at least 200 degrees Celsius within less than 2 seconds, wherein a circuit path is established from the current source to the plurality of coils in the series to the ground wire, with each fuse defining a short-circuit path between each coil and the next adjacent coil in the series, and wherein the current source is further configured to send a short current burst to cause an unfailed fuse closest to the current source to fail, thereby allowing the next adjacent coil in the series to be energized by the current source. 
     
     
         5 . The drug delivery and drug cessation system of  claim 1 , wherein the drug payload comprises a thin film structure comprising a plurality of foils connected in series and a plurality of fuses connected to a ground portion of the thin film structure, each fuse separating each foil from a next adjacent foil in the series, wherein each of the plurality of foils is coated with the drug, wherein the dosage delivery device comprises a current source configured to heat each foil to at least 200 degrees Celsius within less than 2 seconds, wherein a circuit path is established from the current source to the plurality of foils in the series to the ground wire, with each fuse defining a short-circuit path between each foil and the next adjacent foil in the series, and wherein the current source is further configured to send a short current burst to cause an unfailed fuse closest to the current source to fail, thereby allowing the next adjacent foil in the series to be energized by the current source. 
     
     
         6 . The drug delivery and drug cessation system of  claim 5 , wherein the thin film structure has an overall shape of one of a flat foil wrapped in wedge form, a flat foil wrapped in tubular form, or a planar structure. 
     
     
         7 . The drug delivery and drug cessation system of  claim 1 , wherein the drug payload comprises a liquid reservoir containing the drug in liquid form, wherein the dosage delivery device comprises a variable permeability membrane and a membrane actuator, said variable permeability membrane configured to change liquid permeability so as to deliver varying amounts of the drug from the liquid reservoir, based on control signals from the membrane actuator. 
     
     
         8 . The drug delivery and drug cessation system of  claim 1 , wherein the drug payload comprises a plurality of foils arranged in a first grid comprising a first plurality of rows and a first plurality of columns, each foil being coated with the drug and each foil being separated from each other by electrically and thermally non-conductive material, wherein the dosage delivery device comprises a first group of switches, a second group of switches, a current source electrically coupled to each of the first group of switches, an electrical ground path electrically coupled to each of the second group of switches, a plurality of actuators arranged in a second grid comprising a second plurality of rows and a second plurality of columns, a first plurality of linear electrical paths, a second plurality of linear electrical paths, wherein for each column in the second plurality of columns, a first electrical path is established from one of the first group of switches to each of the plurality of actuators arranged in the subject column in the second plurality of columns, wherein for each row in the second plurality of rows, a second electrical path is established from one of the second group of switches to each of the plurality of actuators arranged in the subject column in the second plurality of rows, wherein the plurality of foils arranged in the first grid is aligned with the plurality of actuators arranged in the second grid so as to make direct contact therewith. 
     
     
         9 . The drug delivery and drug cessation system of  claim 8 , wherein each of the plurality of actuators includes a resistive element configured to reach a temperature of at least 200 degrees Celsius within less than 2 seconds with application of a predetermined amount of current, wherein each of the plurality of foils arranged in the first grid is individually heated by closing one of the first group of switches and closing one of the second group of switches, thereby energizing a subject resistive element electrically coupled to both the one of the first group of switches and the one of the second group of switches, in turn heating a subject foil of the plurality of foils that is in direct contact with the subject resistive element. 
     
     
         10 . The drug delivery and drug cessation system of  claim 9 , wherein the dosage delivery device further comprises a membrane in physical contact with the body of the user, wherein the drug heated by the subject foil flows as one of a gas or a liquid through the membrane to be absorbed by a skin portion of the body of the user. 
     
     
         11 . The drug delivery and drug cessation system of  claim 8 , wherein each switch in the first and second group of switches is a transistor. 
     
     
         12 . The drug delivery and drug cessation system of  claim 1 , wherein the drug comprises one of nicotine, nicotine meta-salicylate, or morphine. 
     
     
         13 . The drug delivery and drug cessation system of  claim 1 , further comprising:
 one or more user sensors each adapted to be in contact with a portion of the body of the user, each of the one or more user sensors comprising a third wireless transceiver and one or more measurement sensors, the one or more measurement sensors comprising one or more of an oximeter, a pulse measurement sensor, a respiration rate sensor, or a blood pressure sensor,   wherein the portable drug delivery device is configured to deliver the drug to the body of the user based on instructions received from the portable control device and based on measurement results received from the one or more measurement sensors via the third wireless transceiver.   
     
     
         14 . The drug delivery and drug cessation system of  claim 1 , wherein the portable control device further comprises a memory device and a network interface, wherein the memory device is configured to store a history of drug delivery using the system, the history of drug delivery comprising one or more of drug dosages for predetermined periods, increases in drug dosage, decreases in drug dosage, number of doses for each predetermined period, increases in number of doses for each predetermined period, decreases in number of doses for each predetermined period, number of user-initiated drug delivery overrides, types of user-initiated drug delivery overrides, or contact information of a healthcare professional associated with the user, wherein the network interface communicatively couples with a computing device of the healthcare professional over a network to send the history of drug delivery to the healthcare professional and to receive drug dosage prescriptions from the healthcare professional.